Table 2.
Food and Drug Administration-Approved Indications for Osteoporosis Treatments42–46,49–51,71,75,78,84–86,88,89,93,97
| Drug (Brand, Manufacturer) | Treatment of PMO | Prevention of PMO | Treatment (men) | Treatment of GIO | Prevention of GIO |
|---|---|---|---|---|---|
| Alendronate (Fosamax, Merck) | x | x | x | x | x |
| Alendronate/cholecalciferol (Fosamax Plus D, Merck) | x | x | |||
| Alendronate effervescent (Binosto, Mission Pharmacal) | x | x | |||
| Risedronate IR (Actonel, Warner Chilcott) | x | x | x | x | x |
| Risedronate DR (Atelvia, Warner Chilcott) | x | ||||
| Ibandronate injection (Boniva, Genentech) | x | ||||
| Ibandronate tablets (Boniva, Genentech) | x | x | |||
| Zoledronic acid (Reclast, Novartis) | x | x | x | x | x |
| Denosumab (Prolia, Amgen)a | x | x | |||
| Raloxifene (Evista, Lilly USA) | x | x | |||
| Conjugated estrogens/bazedoxifene (Duavee, Pfizer) | x | ||||
| Teriparatide (Forteo, Lilly USA)b | x | c | x | ||
| Abaloparatide (Tymlos, Radius Health) | x | ||||
| Calcitonin-salmond | x |
a
Also indicated to increase bone mass in women and men at high risk of fracture without osteoporosis.
b
Treatment only for those at high risk of fracture.
c
Increases bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture.
d
Miacalcin injection (Novartis) is indicated for the treatment of PMO in women more than five years postmenopause when alternative treatments are not suitable.
GIO = glucocorticoid-induced osteoporosis; PMO = postmenopausal osteoporosis.